Swedish startup Neko Health, founded by Spotify co-founder Daniel Ek, has announced a $700 million Series C funding round to bring its AI-powered body scans to the United States, starting with a clinic in New York. The company, which already operates eight centers in the UK and Sweden, combines medical imaging, blood tests, proprietary sensors, and clinical review in a one-hour preventive screening service. The round was led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from existing investors such as Atomico, General Catalyst, and Lakestar, as well as new backers including Liberty City Ventures, Positive Sum, and BDT & MSD. Prominent figures like Mark Zuckerberg, Priscilla Chan, Maria Sharapova, will.i.am, and Thierry Henry also invested. Neko's total disclosed funding since 2023 now exceeds $1 billion, and according to sources close to the Financial Times, the company is valued at around $7 billion.
Neko's business model relies on physical clinics where customers undergo a full assessment including a high-resolution body scan, electrocardiogram, arterial measurements, body composition analysis, and over 2,000 skin images. The process is non-invasive and radiation-free. Blood is processed on-site so results are available during the same visit, and a physician reviews findings in a face-to-face consultation. The company claims to have performed 100,000 scans since its 2023 launch, with over 350,000 people on waiting lists. Moreover, 75% of customers pre-book and prepay for a second appointment, enabling longitudinal comparisons.
Behind this preventive health promise lies a complex technological architecture involving artificial intelligence, proprietary sensors, image processing, and massive data analytics. Neko's internal devices, such as the Derma-2, Echo, and Spectrum-2 systems, have received FDA clearance through the 510(k) pathway for specific uses like telethermography and tissue saturation oximetry. However, the company makes clear that the complete scan service is not approved as an independent diagnostic test, but as a preventive wellness tool. Customers must still consult their primary care physicians for diagnoses and treatments.
For a company like Neko, which handles sensitive health data and aims to expand into the heavily regulated US market, robust technological infrastructure is critical. This is where solutions like custom software development offered by Q2BSTUDIO come into play. Q2BSTUDIO specializes in multi-platform application development, artificial intelligence, and cloud computing. Neko needs strong systems to manage data flow from sensors to clinical reports, secure cloud storage, AI-driven analysis, and integration with electronic health records.
AI is the core of Neko's value proposition: its algorithms classify skin images, detect anomalies in ECGs and metabolic markers, and generate preliminary reports later reviewed by clinicians. But AI doesn't work alone; it requires a solid data training foundation, a scalable cloud architecture (AWS or Azure), and cybersecurity measures to protect patient privacy. Q2BSTUDIO offers precisely that: cloud services on AWS and Azure, cybersecurity solutions, and Business Intelligence platforms like Power BI to analyze population health trends.
Neko's approach raises questions about clinical evidence. Although the company has published data from 1,469 returning customers showing improvements in blood pressure, cholesterol, and blood sugar, Neko itself admits this is not a controlled scientific study. There is no control group, and customers may have changed behavior or received medical treatment between visits. Moreover, no peer-reviewed studies validate the complete service. The FDA only approved individual devices, not the scan as a whole. This sparks debate on whether the preventive subscription model truly improves clinical outcomes or simply generates high false-positive rates leading to unnecessary follow-ups.
From a business perspective, US expansion is a risky but enormous market of health-conscious consumers willing to pay out-of-pocket. Neko has not yet disclosed US scan prices, but in the UK they cost £299 (about $400) and in Sweden SEK 2,750 ($285). The company does not participate in health insurance, limiting its reach to high-income individuals. To scale, it will need to demonstrate cost savings for healthcare systems, something investors and payers will demand.
In this context, partnerships with technology development firms like Q2BSTUDIO can make a difference. Not only in building custom applications for appointment management, image processing, and data analysis, but also in deploying AI agents to automate repetitive tasks, improve diagnostic accuracy, and optimize clinical workflows. Process automation, combined with cloud and BI, allows startups like Neko to focus on their value proposition while outsourcing underlying technology to specialists.
The market for AI-driven preventive health is booming. Companies like Prenuvo, Ezra, and Neko compete to offer full-body scans with artificial intelligence. But the key to success lies not just in sensors, but in the ability to securely and efficiently process, store, and analyze vast amounts of data. That's where Q2BSTUDIO's expertise in cloud AWS/Azure, cybersecurity, and Business Intelligence (Power BI) becomes a strategic enabler. Companies aiming to launch similar products should consider technology partnerships covering everything from software development to real-time data analytics.
Ultimately, Neko Health's $700 million round is a milestone reflecting investor confidence in the convergence of AI and preventive medicine. However, the path to mass adoption will require not only more funding, but also robust technological infrastructure, solid clinical evidence, and clear regulation. Companies like Q2BSTUDIO, with experience in custom applications, AI, cloud, and cybersecurity, are natural partners to build that infrastructure. The future of preventive health is written in code, data, and algorithms, and the companies that master this combination will lead the next decade.
